On October 7, 2022, Stephanie M. Geveda notified Sotera Health Company of her resignation as a director of the Company, effective October 7, 2022, in connection with her departure from Warburg Pincus LLC. On October 12, 2022, the Board appointed Robert B. Knauss to serve as a director of the Company, effective October 12, 2022. Mr. Knauss is a Managing Director at Warburg Pincus.

Mr. Knauss will join the Board as a Class III director, and his term will expire with the terms of the other Class III directors at the 2023 annual meeting of stockholders. Pursuant to the Company's Stockholders Agreement, for so long as funds affiliated with Warburg Pincus collectively own a specified number of Company shares, Warburg Pincus has the right to designate a certain number of directors to the Company's Board. In the event a Warburg Pincus designee resigns from the Board, Warburg Pincus has the right to designate a replacement, and Warburg Pincus, the Company and stockholder funds affiliated with GTCR LLC are required to take necessary action to cause Warburg Pincus's desired replacement to be appointed or elected to the Board.

Mr. Knauss is entering into a customary indemnification agreement with the Company in connection with his appointment as a director, consistent with those entered into with the Company's other directors, pursuant to which the Company agrees to provide indemnification and advancement of expenses to the fullest extent permitted by law and the Company's amended and restated certificate of incorporation and amended and restated bylaws. Mr. Knauss has been deemed to be independent" in accordance with Rule 5605(a)(2) of the Nasdaq Marketplace Rules. Other than the disclosure as further described in the Company's Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 14, 2022 (the Proxy Statement") related to the beneficial ownership of Company shares representing a majority of the outstanding shares of the Company's common stock by funds affiliated with Warburg Pincus and GTCR LLC, there are no transactions between Mr. Knauss and the Company that require disclosure pursuant to Item 404(a) of Securities and Exchange Commission Regulation S-K or the Company's related party transaction policy.